F-star’s discovery engine rapidly creates bispecific antibodies by introducing target binding sites to the antibody constant region. F-star is the only biopharmaceutical company creating bispecific antibodies by modifying the constant region of an antibody and their Modular Antibody Technology offers unprecedented ease in the development and manufacturing of bispecific antibody products. F-Star is based in Vienna, Austria,with an R&D site in Cambridge, UK.


Latest News Entry
F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology

F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck, a leading science and technology company, for the development and commercialisation of five bispecific immuno-oncology antibodies (mAb2 TM).

F-star Enters into Collaborative Discovery & Development Agreement with AbbVie for Bispecific Antibodies in Immuno-oncology

F-star today announced that it has entered into a collaboration and license agreement with AbbVie to research and develop bispecific antibodies in immuno-oncology.

F-star Appoints Dr Neil Brewis as Chief Scientific Officer

Dr Brewis joins F-star from GlaxoSmithKline (GSK) where as Vice President, Head of Biopharmaceutical Research he led a global team of 300 scientists who advanced numerous monoclonal

all portfolio news